Research

Clinical Trials

Active dermatology clinical trials enrolling patients in Connecticut — coordinator contacts, eligibility criteria, and referral information for physicians.

Active Trials
Enrolling Now Phase III Atopic Dermatitis
Novel IL-31 Inhibitor for Moderate-to-Severe Atopic Dermatitis in Adults
NCT05xxxxxx
A randomized, double-blind, placebo-controlled Phase III study evaluating the efficacy and safety of a novel IL-31 receptor antagonist in adults with moderate-to-severe atopic dermatitis who have had an inadequate response to topical therapies. Study duration is 52 weeks with an optional open-label extension period.
Sponsor Industry Sponsored
Site Yale Dermatology, New Haven
Target Enrollment 40 Patients
Age Range 18–75 years
Duration 52 weeks
Compensation Study provided
Principal Investigator Keith Choate, M.D. Yale Dept. of Dermatology
Study Coordinator Contact for Details trials@yaledermatology.edu
Refer a Patient
Enrolling Now Phase II Psoriasis
TYK2 Inhibitor Combination Therapy for Plaque Psoriasis — Long-Term Safety Extension
NCT04xxxxxx
An open-label long-term safety and efficacy extension study of a selective TYK2 inhibitor in combination with a standard biologic for patients with moderate-to-severe plaque psoriasis. Patients who completed the Phase II core study or who are biologic-naive may be eligible.
Sponsor Industry Sponsored
Site UConn Dermatology, Farmington
Target Enrollment 25 Patients
Age Range 18+ years
Duration 104 weeks
Compensation Study provided
Principal Investigator To be confirmed UConn Dept. of Dermatology
Study Coordinator Contact for Details research@uconndermatology.edu
Refer a Patient
Enrolling Now Phase III Cutaneous Oncology
Adjuvant PD-1 Inhibitor Therapy Following Mohs Surgery for High-Risk Squamous Cell Carcinoma
NCT06xxxxxx
A multicenter Phase III trial evaluating adjuvant PD-1 checkpoint inhibitor therapy versus observation in patients with high-risk cutaneous squamous cell carcinoma following complete Mohs micrographic surgical excision. Eligibility includes tumor diameter greater than 2 cm, perineural invasion, or deep tissue involvement.
Sponsor NCI Cooperative Group
Site Yale Cancer Center, New Haven
Target Enrollment Multicenter — 300
Age Range 18+ years
Duration 24 months
Compensation Travel reimbursement
Principal Investigator Matthew Vesely, M.D. Yale Cancer Center
Study Coordinator Contact for Details research@yalecancer.edu
Refer a Patient
Enrollment Closed Phase II Atopic Dermatitis
Topical JAK Inhibitor for Mild Atopic Dermatitis in Pediatric Patients
NCT03xxxxxx
Enrollment is now closed for this Phase II study of a topical JAK1/2 inhibitor in pediatric patients ages 6–17 with mild-to-moderate atopic dermatitis. Results are expected Q3 2025. Contact the coordinator for information about related future studies.
Status Enrollment Closed
Site Yale Dermatology
Results Expected Q3 2025
Principal Investigator Keith Choate, M.D. Yale Dept. of Dermatology
Future Studies Inquiries Welcome trials@yaledermatology.edu
Enrollment closed

Currently Enrolling

Atopic Dermatitis
IL-31 Inhibitor — Phase III
Yale Dermatology · Adults 18–75
Psoriasis
TYK2 Inhibitor Extension — Phase II
UConn Dermatology · Adults 18+
Cutaneous Oncology
PD-1 Inhibitor Post-Mohs — Phase III
Yale Cancer Center · Adults 18+

Key Contacts

Yale — Chair, Dept. of Dermatology
Keith Choate, M.D.
Yale Dermatology →
CTDS Executive Director
Debbie Osborn
(860) 567-3787
debbieosborn36@yahoo.com
National Trial Registry
ClinicalTrials.gov
Search all active trials →

Research Resources

ClinicalTrials.govNational trial registry
→
AAD Research Resourcesaad.org
→
NIAMS — NIHSkin disease research
→
Yale DermatologyResearch programs
→
Process

How to Refer a Patient

Referring a patient to a clinical trial is straightforward. Follow these steps or use the referral form below to connect directly with the study coordinator.

01
Review Eligibility
Check the trial's inclusion and exclusion criteria against your patient's diagnosis, age, treatment history, and comorbidities.
02
Contact the Coordinator
Call or email the study coordinator listed on the trial. They will conduct a pre-screening discussion with you or your patient.
03
Submit a Referral
Use the form below to submit a referral inquiry. Include a general patient description — no PHI required at this stage.
04
Coordinate Consent
The trial site handles informed consent, baseline assessments, and scheduling. You will receive updates on your patient's enrollment status.
Patient Referral

Submit a Referral Inquiry

Use this form to express interest in referring a patient to one of the Society's active trials. A coordinator will follow up to discuss eligibility and next steps.

Do not include patient-identifying information in this form. All PHI should be shared only through secure, HIPAA-compliant channels with the study coordinator directly.

General Inquiries Debbie Osborn — Executive Director
(860) 567-3787
debbieosborn36@yahoo.com
Privacy Notice
Do not submit protected health information (PHI) in this form. A coordinator will contact you via secure channel to discuss patient specifics.

A study coordinator will respond within two business days.